1. Home
  2. RLAY vs PBLS Comparison

RLAY vs PBLS Comparison

Compare RLAY & PBLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Relay Therapeutics Inc.

RLAY

Relay Therapeutics Inc.

N/A

Current Price

$18.66

Market Cap

4.1B

Sector

Health Care

ML Signal

N/A

Logo Parabilis Medicines Inc. Common Stock

PBLS

Parabilis Medicines Inc. Common Stock

N/A

Current Price

$38.76

Market Cap

3.6B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
RLAY
PBLS
Founded
2015
N/A
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
4.1B
3.6B
IPO Year
2020
2026

Fundamental Metrics

Financial Performance
Metric
RLAY
PBLS
Price
$18.66
$38.76
Analyst Decision
Strong Buy
Analyst Count
10
0
Target Price
$19.50
N/A
AVG Volume (30 Days)
2.2M
351.6K
Earning Date
05-05-2026
N/A
Dividend Yield
N/A
N/A
EPS Growth
31.78
N/A
EPS
N/A
N/A
Revenue
$15,355,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$324.03
N/A
P/E Ratio
N/A
N/A
Revenue Growth
53.44
N/A
52 Week Low
$3.89
$25.56
52 Week High
$21.27
$41.49

Technical Indicators

Market Signals
Indicator
RLAY
PBLS
Relative Strength Index (RSI) 45.13 56.63
Support Level $18.00 $37.88
Resistance Level $20.82 $41.49
Average True Range (ATR) 0.80 1.93
MACD -0.13 -0.28
Stochastic Oscillator 28.24 31.28

Price Performance

Historical Comparison
RLAY
PBLS

About RLAY Relay Therapeutics Inc.

Relay Therapeutics Inc is a clinical-stage precision medicine company transforming the drug discovery process and bringing life-changing therapies to patients. The Dynamo platform of the company integrates an array of leading-edge computational and experimental approaches designed to drug-protein targets that have previously been intractable or inadequately addressed. The company is advancing a pipeline of medicine candidates to address targets in precision oncology and genetic disease, including product candidates, RLY-8186, RLY-2608, RLY-4008 and others.

About PBLS Parabilis Medicines Inc. Common Stock

Parabilis Medicines Inc s a clinical-stage biopharmaceutical company. It is focused on the development of medicines targeting protein interactions associated with human diseases. It uses a proprietary platform to develop stabilized helical peptide therapeutics, referred to as Helicons, designed to bind and modulate specific proteins. Its flagship product candidate, zolucatetide, targets the interaction between β-catenin and the T-cell factor (TCF) family of transcription factors within the Wnt/β-catenin signaling pathway, which is associated with cell proliferation and differentiation in multiple cancer types.

Share on Social Networks: